Michael J. Morris, MD, on the Alliance Trial: Clinical Implications of Combination Therapy for Prostate Cancer

Posted: Monday, June 24, 2019

Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses whether the combination of abiraterone acetate and enzalutamide will play a role in the future treatment of metastatic castration-resistant prostate cancer.